Pet Cancer Therapeutics Market will grow at 7.7% CAGR, to be valued at US$ 332.6 Million by 2025
SEATTLE, March 17, 2021, (PHARMIWEB) —
Global Pet Cancer Therapeutics Market – Efficient Cancer Cure in Companion Animals
Pet cancer therapeutics are innovative drug molecules that possess high potential to reduce the effects of cancer, while providing access to comprehensive cancer care with least side effects. The primary aim of cancer therapies is to eliminate cancerous cells prevalent in animals. Moreover, veterinarians recommend specific treatment program such as targeted therapy and combination therapy or chemotherapy in according with the type of cancer, stage, and nature of the cancer. Researchers and scientists around the globe are developing novel formulations and therapies for pet cancer therapeutics, which is expected to drive growth of the global pet cancer therapeutics market. For instance, the scientists at University of Veterinary Medicine are currently exploring the molecular basis of cancer progression in canine cell lines, stating that the modern cancer therapy can be revolutionized with the introduction of targeted therapies.
The global pet cancer therapeutics market is estimated to be valued at US$ 183.3 million in 2017 and is expected to witness a robust CAGR of 7.7% over the forecast period (2017 – 2025).
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/1284
Figure 1. Global Pet Cancer Therapeutics Market (US$ Mn), by Region, 2017
Growing R&D activities in cancer management to drive the market growth
Researchers around the global are receiving enhanced research grants or the development of anti-cancer therapies, which is expected to drive the global pet cancer therapeutics market growth during the forecast period. For instance, in 2017, Animal Cancer Foundation (ACF) received a US$ 1 million grant from the Blue Buffalo Foundation to support comparative oncology research, which is aimed to study similarities between naturally occurring cancers in people and pets and find effective treatment in both species. Furthermore, in 2016, the Petco Foundation and Blue Buffalo Foundation invested US$ 2.35 million to support pet cancer research and treatment, as it represents a major cause of illness and premature death in affected species worldwide. Moreover, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to create a biobank of dog tumors for providing insights on cancer cure through research, in order to develop the most effective cancer therapy. Various organizations such as Animal Cancer Foundation, Petco Foundation, Veterinary Cancer Society, and PetCure Oncology are conducting oncology research such as ‘Canine Cancer Genome’ project to comprehend the genetic makeup of cancer tumors in animals, in order to innovate targeted drug therapies with minimum toxic effects. However, growing adoption of alternative treatment methods such as herbal medications and homeopathy coupled with adverse effects such as diarrhea, musculoskeletal disorder, anorexia, and expensive pet cancer treatment are expected to restrain the market growth during the forecast period.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Quick Buy – Pet Cancer Therapeutics Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1284
Increasing incidence and remission rates of pet cancers to accelerate the market growth
Increasing prevalence of cancer cases has led to adoption of novel therapies, which are proved to be highly effective for the treatment of cancers in pets, which is eventually augmenting the global pet cancer therapeutics market growth during the forecast period. According to Fetch a Cure’s study, 2015, dogs and cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer. According to the study published by Animal Cancer Foundation, 2017, around 25% of all dogs will develop a tumor at some point in their life. Furthermore, increasing cases of relapsed cancer rates and the availability of relapsed/ refractory therapeutics incorporated with veterinarian recommendation is expected to boost the market growth in the near future. For instance, according to the study by petMD, LLC, 2015, around 95% of dogs treated for lymphoma with chemotherapy protocols and conventional treatments are expected to experience disease relapse or remission. The duration of remission is less than 15 months in 50% of dog species. In 2017, a novel chemotherapy drug named Tanovea-CA1 (rabacfosadine for injection), manufactured by VedDC, Inc. was conditionally approved by the U.S. Food and Drug Administration (FDA) as a first line treatment for dogs to treat relapsed/refractory lymphoma and canine lymphoma. Such conditional approvals of drug has allowed the manufacturers to legally sell Tanovea-CA1, before proving it meets the substantial evidence standard of effectiveness for full approval.
Key companies operating the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/rising-number-of-approvals-from-regulatory-agencies-to-surge-pet-cancer-therapeutics-market-beyond-us-3326-million-by-2025-593
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Pet Type
- Market Snippet, By Mode of Administration
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Key Highlights
- Pipeline Analysis
- Regulatory Guidelines
- Initiatives for Prevention of Pet Cancer
- Approved Targeted Therapies for Pet Cancer
- Epidemiology
- Market Dynamics
- Global Pet Cancer Therapeutics Market, By Therapy Type, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- Introduction
- Global Pet Cancer Therapeutics Market, By Pet Type, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Cat
- Dog
- Horse
- Introduction
- Global Pet Cancer Therapeutics Market, By Mode of Administration, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Oral
- Intravenous
- Topical
- Introduction
- Global Pet Cancer Therapeutics Market, By Application, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
- Introduction
- Global Pet Cancer Therapeutics Market, By Region, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2025
- North America
- Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3×3 Matrix)
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
